評論
打印
There is also evidence that the drugs may cause serious harm. One example is described by Michael Biggs of Oxford University in a letter published on April 26th in the Journal of Paediatric Endocrinology and Metabolism. Bone-mineral density (BMD) usually rises sharply in puberty. But of 24 GIDS patients who had been prescribed puberty blockers, a third had BMD scores in the bottom 2% of their age groups (more that two standard deviations below the mean).
也有證據(jù)表明，這些藥物可能會造成嚴重的傷害。牛津大學的邁克爾·比格斯在4月26日發(fā)表在兒科內(nèi)分泌和代謝雜志上的一封信中描述了一個例子。骨密度(BMD)通常在青春期急劇上升。但是在24名服用了青春期阻滯藥的GIDS患者中，有三分之一的骨密度評分在其年齡組的最后2%(比平均值低兩個標準差以上)。
One patient, who began puberty blockers aged 12, suffered four fractures by the age of 16. That medical history, says Dr Biggs, would usually be enough to diagnose osteoporosis—normally a disease of the elderly. Animal studies suggest puberty blockers may cause cognitive damage, too. Cross-sex hormones have been linked to heart disease, strokes and sterility.
一名患者在12歲時開始服用青春期阻斷劑，16歲時發(fā)生了四次骨折。比格斯博士說，這種病史通常足以診斷為骨質(zhì)疏松癥——老年人中常見的一種疾病。動物研究表明，青春期阻斷劑也可能會導(dǎo)致認知損傷。跨性別激素與心臟病、中風和不育有關(guān)。
The combination of rising prescriptions and flimsy evidence leads some doctors to fear a medical scandal is brewing. Others think that the only scandal would be to change course. A bill before Canada's parliament, for instance, would leave affirmation as the only legal treatment for gender dysphoria. The argument continues.
越來越多的處方和越來越多的證據(jù)使一些醫(yī)生擔心一場醫(yī)療丑聞?wù)卺j釀之中。其他人則認為唯一的丑聞就是改弦更張。例如，一項提交給加拿大議會的法案將把“肯定療法”作為唯一合法的針對性別焦慮的治療方法。爭論仍在繼續(xù)。
譯文由可可原創(chuàng)，僅供學習交流使用，未經(jīng)許可請勿轉(zhuǎn)載。
